US92243G1085 - Common Stock
VAXCYTE INC
NASDAQ:PCVX (5/8/2024, 7:11:37 PM)
After market: 66.79 0 (0%)66.79
-0.73 (-1.08%)
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 158 full-time employees. The company went IPO on 2020-06-12. The firm develops conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its synthetic techniques include advanced chemistry and the XpressCF cell-free protein synthesis platform, licensed from Sutro Biopharma, Inc., or Sutro Biopharma. Its pipeline includes Pneumococcal conjugate vaccine (PCV), VAX-A1, VAX-PG and VAX-GI. Its lead vaccine candidate, VAX-24, is a 24-valent investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD). Its second PCV candidate, VAX-31, is designed to prevent IPD. population. VAX- 24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults. VAX-A1 is a conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus or Group A Strep. VAX-PG is a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. VAX-GI is a vaccine program designed to prevent Shigella.
VAXCYTE INC
825 Industrial Road, Ste. 300
San Carlos CALIFORNIA 94404
P: 16508370111
CEO: Grant E. Pickering
Employees: 158
Website: https://vaxcyte.com/
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxcyte (NASDAQ:PCVX) just reported results for the first quarter of 2024.Vaxcy...
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Here you can normally see the latest stock twits on PCVX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: